Patients with diabetes show poor adherence to heart disease drugs

Adherence to heart disease therapies dropped by half within one year

February 21, 2019

Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes

This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.

  • Glucagon like peptide-1 agonists (GLP-1)
    Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
    Dipeptidyl peptidase-4 inhibitors (DPP-4i)

All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90% in their clinical trials.)

Among Commercially Insured Members with Diabetes Mellitus (DM), Choice and Persistence of Drug Therapy: Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Versus Glucagon-like Peptide-1 Agonists (GLP-1) or Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) (Fall 2018)

Related news

Perspectives

September 25, 2023

Specialty Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

September 25, 2023

Traditional Drug Pipeline Quarterly Update: September 2023

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Perspectives

September 25, 2023

Gene/Cell Therapy Quarterly Update: September 2023

This quarterly pipeline wrap-up provides a review of newly approved gene and cell…